Mephedrone ("bath salt") pharmacology: Insights from invertebrates

Neuroscience

Volumn 208, Issue , 2012, Pages 79-84

  Ramoz, L ^a   Lodi, S ^a   Bhatt, P ^a   Reitz, A B ^b   Tallarida, C ^a   Tallarida, R J ^a,c   Raffa, R B ^c   Rawls, S M ^a,c  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fox Chase Chemical Diversity Center Inc   (United States)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

Dopamine; Mephedrone; Motility; Place preference; Planarians; Withdrawal

Indexed keywords

4' METHYLMETHCATHINONE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE RECEPTOR;

ABSTINENCE; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONDITIONING; CONTROLLED STUDY; LOCOMOTION; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; STEREOTYPY; TURBELLARIA;

ANIMALS; BEHAVIOR, ANIMAL; BENZAZEPINES; CENTRAL NERVOUS SYSTEM STIMULANTS; CONDITIONING, OPERANT; DATA INTERPRETATION, STATISTICAL; DOPAMINE ANTAGONISTS; ENVIRONMENT; INVERTEBRATES; METHAMPHETAMINE; PLANARIANS; STEREOTYPED BEHAVIOR; STREET DRUGS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84858623526     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.01.019     Document Type: Article

References (42)

1. Algeri S., Carolei A., Ferretti P., Gallone C., Palladini G., Venturini G. Effects of dopaminergic agents on monoamine levels and motor behaviour in planaria. Comp Biochem Physiol C 1983, 74:27-29.
2. Al-Motarreb A., Al-Habori M., Broadley K.J. Khat chewing, cardiovascular diseases and other internal medical problems: the current situation and directions for future research. J Ethnopharmacol 2010, 132:540-548.
3. Bourne J.A. SCH 23390: the first selective dopamine D1-like receptor antagonist. CNS. Drug Res 2001, 7:399-414.
4. Buttarelli F.R., Pontieri F.E., Margotta V., Palladini G. Acetylcholine/dopamine interaction in planaria. Comp Biochem Physiol C Toxicol Pharmacol 2000, 125:225-231.
5. Chae Y., Yeom M., Han J.H., Park H.J., Hahm D.H., Shim I., Lee H.S., Lee H. Effect of acupuncture on anxiety-like behavior during nicotine withdrawal and relevant mechanisms. Neurosci Lett 2008, 430:98-102.
6. Creese I., Iversen S.D. The role of forebrain dopamine systems in amphetamine induced stereotyped behavior in the rat. Psychopharmacologia 1974, 39:345-357.
7. Eriksson K.S., Panula P. Gamma-aminobutyric acid in the nervous system of a planarian. J Comp Neurol 1994, 345:528-536.
8. Hadlock G.C., Webb K.M., McFadden L.M., Chu P.W., Ellis J.D., Allen S.C., Andrenyak D.M., Vieira-Brock P.L., German C.L., Conrad K.M., Hoonakker A.J., Gibb J.W., Wilkins D.G., Hanson G.R., Fleckenstein A.E. 4-Methylmethcathinone(mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 2011, 339:530-536.
9. Hyttel J. SCH 23390-the first selective dopamine D-1 antagonist. Eur J Pharmacol 1983, 91:153-154.
10. Kehr J., Ichinose F., Yoshitake S., Goiny M., Sievertsson T., Nyberg F., Yoshitake T. Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats. Br J Pharmacol 2011, 164:1949-1958.
11. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992, 13:177-184.
12. Kusayama T., Watanabe S. Reinforcing effects of methamphetamine in planarians. Neuroreport 2000, 11:2511-2513.
13. Martínez-Clemente J., Escubedo E., Pubill D., Camarasa J. Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol 2012, 22:231-236.
14. Meyer M.R., Wilhelm J., Peters F.T., Maurer H.H. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 2010, 397:1225-1233.
15. Newcombe R. Mephedrone: use of Mephedrone (M-Cat, Meow) in Middlesbrough 2009, Lifeline Publications, Manchester, UK.
16. Nishimura K., Kitamura Y., Taniguchi T., Agata K. Analysis of motor function modulated by cholinergic neurons in planarian Dugesia japonica. Neuroscience 2010, 168:18-30.
17. Pagán O.R., Rowlands A.L., Azam M., Urban K.R., Bidja A.H., Roy D.M., Feeney R.B., Afshari L.K. Reversal of cocaine-induced planarian behavior by parthenolide and related sesquiterpene lactones. Pharmacol Biochem Behav 2008, 89:160-170.
18. Pagán O.R., Rowlands A.L., Fattore A.L., Coudron T., Urban K.R., Bidja A.H., Eterović V.A. A cembranoid from tobacco prevents the expression of nicotine-induced withdrawal behavior in planarian worms. Eur J Pharmacol 2009, 615:118-124.
19. Palladini G., Ruggeri S., Stocchi F., De Pandis M.F., Venturini G., Margotta V. A pharmacological study of cocaine activity in planaria. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1996, 115:41-45.
20. Mephedrone report 2009, Psychonaut Web Mapping Research Group, Institute of Psychiatry, King's College London, London, UK.
21. Raffa R.B., Dasrath C.S., Brown D.R. Disruption of a drug-induced choice behavior by UV light. Behav Pharmacol 2003, 14:569-571.
22. Raffa R.B., Desai P. Description and quantification of cocaine withdrawal signs in planaria. Brain Res 2005, 1032:200-2002.
23. Raffa R.B., Finno K.E., Tallarida C.S., Rawls S.M. Topiramate-antagonism of L-glutamate-induced paroxysms in planarians. Eur J Pharmacol 2010, 649:150-153.
24. Raffa R.B., Rawls S.M. A model for drug action and abuse 2008, Landes Bioscience, Austin, TX.
25. Raffa R.B., Stagliano G.W., Ross G., Powell J.A., Phillips A.G., Ding Z., Rawls S.M. The kappa-opioid receptor antagonist nor-BNI inhibits cocaine and amphetamine, but not cannabinoid (WIN 52212-2), abstinence-induced withdrawal in planarians: an instance of "pharmacologic congruence". Brain Res 2008, 1193:51-56.
26. Raffa R.B., Valdez J.M. Cocaine withdrawal in planaria. Eur J Pharmacol 2001, 430:143-145.
27. Ramakrishnan L., Desaer C. Carbamazepine inhibits distinct chemoconvulsant-induced seizure-like activity in Dugesia tigrina. Pharmacol Biochem Behav 2011, 99:665-670.
28. Rawls S.M., Gomez T., Raffa R.B. An NMDA antagonist (LY235959) attenuates abstinence-induced withdrawal of planarians following acute exposure to a cannabinoid agonist (WIN 55212-2). Pharmacol Biochem Behav 2007, 86:499-504.
29. Rawls S.M., Patil T., Yuvasheva E., Raffa R.B. First evidence that drugs of abuse produce behavioral sensitization and cross sensitization in planarians. Behav Pharmacol 2010, 21:301-313.
30. Rawls S.M., Karaca F., Madhani I., Bhojani V., Martinez R.L., Abou-Gharbia M., Raffa R.B. β-lactamase inhibitors display anti-seizure properties in an invertebrate assay. Neuroscience 2010, 169:1800-1804.
31. Rawls S.M., Patil T., Tallarida C.S., Baron S., Kim M., Song K., Ward S., Raffa R.B. Nicotine behavioral pharmacology: clues from planarians. Drug Alcohol Depend 2011, 118:274-279.
32. Rawls S.M., Thomas T., Adeola M., Patil T., Raymondi N., Poles A., Loo M., Raffa R.B. Topiramate antagonizes NMDA- and AMPA-induced seizure-like activity in planarians. Pharmacol Biochem Behav 2009, 93:363-367.
33. Rowlands A.L., Pagán O.R. Parthenolide prevents the expression of cocaine-induced withdrawal behavior in planarians. Eur J Pharmacol 2008, 583:170-172.
34. Sacavage S., Patel H., Zielinski M., Acker J., Phillips A.G., Raffa R.B., Rawls S.M. Withdrawal-like behavior in planarians is dependent on drug exposure duration. Neurosci Lett 2008, 439:84-88.
35. Schifano F., Corkery J. Cocaine/crack cocaine consumption, treatment demand, seizures, related offences, prices, average purity levels and deaths in the UK (1990-2004). J Psychopharmacol 2008, 22:71-79.
36. Stepens A., Logina I., Liguts V., Aldins P., Eksteina I., Platkājis A., Mārtinsone I., Tēcrauds E., Rozentāle B., Donaghy M. A parkinsonian syndrome in Methcathinone users and the role of manganese. N Engl J Med 2008, 358:1009-1017.
37. Ujike H., Onoue T., Akiyama K., Hamamura T., Otsuki S. Effects of selective D-1 and D-2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization. Psychopharmacology 1989, 98:89-92.
38. Vyas C.A., Rawls S.M., Raffa R.B., Shackman J.G. Glutamate and aspartate measurements in individual planaria by rapid capillary electrophoresis. J Pharmacol Toxicol Methods 2010, 63:119-122.
39. Winstock A., Mitcheson L., Marsden J. Mephedrone: still available and twice the price. Lancet 2010, 376:1537.
40. Winstock A.R., Mitcheson L.R., Deluca P., Davey Z., Corazza O., Schifano F. Mephedrone, new kid for the chop?. Addiction 2011, 106:154-161.
41. Wood D.M., Davies S., Greene S.L., Button J., Holt D.W., Ramsey J., Dargan P.I. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol 2010, 48:924-927.
42. Zagnoni P.G., Albano C. Psychostimulants and epilepsy. Epilepsia 2002, 43(Suppl 2):28-31.